Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10
Rhea-AI Summary
Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced its participation in the iAccess Alpha Virtual Best Ideas Winter Conference 2024. The event will take place on December 10th and 11th, 2024.
Dr. Amit Kumar, CEO of Anixa, will deliver a presentation on Tuesday, December 10th at 2:00 p.m. EST. The company's management team will be available for one-on-one meetings with qualified investors on Wednesday, December 11th.
The conference, hosted by iAccess Alpha, features companies recommended by an investor network and follows a two-day format with company webcasts on the first day and one-on-one management meetings on the second day.
Positive
- None.
Negative
- None.
News Market Reaction – ANIX
On the day this news was published, ANIX declined 2.41%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Dr. Amit Kumar, CEO of Anixa, is scheduled to present on Tuesday, December 10th at 2:00 p.m. Eastern Standard Time. To register and access the presentation, please visit https://www.webcaster4.com/Webcast/Page/3074/51704.
Management will also be available for one-on-one meetings with approved qualified investors on Wednesday, December 11th. To register for a one-on-one meeting, please visit the conference website at https://www.iaccessalpha.com/home.
iAccess Alpha hosts virtual investor conferences, where presenting companies are recommended by a network of investors. The conference format spans two days, with company webcast presentations on day one, followed by one-on-one meetings with company management teams on day two.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-iaccess-alpha-virtual-best-ideas-winter-conference-2024-on-december-10-302321961.html
SOURCE Anixa Biosciences, Inc.
FAQ
When is Anixa Biosciences (ANIX) presenting at the iAccess Alpha Winter Conference 2024?
How can investors attend Anixa's (ANIX) presentation at the iAccess Alpha Conference?
What is the format of the iAccess Alpha Conference where Anixa (ANIX) is presenting?
Will Anixa Biosciences (ANIX) be available for individual investor meetings?
